Torrent Pharmaceuticals Ltd. - Research Center
500420 TORNTPHARM Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Sep' 23 | Jun' 23 | Mar' 23 | Dec' 22 | Sep' 22 | |
|---|---|---|---|---|---|
| Sales | 2,146.00 | 2,121.00 | 1,920.00 | 1,857.00 | 1,928.00 |
| Operating profit | 736.00 | 737.00 | 578.00 | 585.00 | 620.00 |
| Interest | 77.00 | 90.00 | 94.00 | 91.00 | 62.00 |
| Gross profit | 674.00 | 658.00 | 510.00 | 509.00 | 569.00 |
| EPS (Rs) | 9.66 | 9.54 | 6.47 | 6.77 | 8.04 |
Quarterly
results in details
| Sep' 23 | Jun' 23 | Mar' 23 | Dec' 22 | Sep' 22 | |
|---|---|---|---|---|---|
| Other income | 15.00 | 11.00 | 26.00 | 15.00 | 11.00 |
| Stock adjustment | -46.00 | -40.00 | -1.00 | 37.00 | 95.00 |
| Raw material | 433.00 | 434.00 | 387.00 | 349.00 | 351.00 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 366.00 | 369.00 | 327.00 | 297.00 | 298.00 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 657.00 | 621.00 | 629.00 | 589.00 | 564.00 |
| Provisions made | - | - | - | - | - |
| Depreciation | 192.00 | 183.00 | 182.00 | 156.00 | 156.00 |
| Taxation | 155.00 | 152.00 | 109.00 | 124.00 | 141.00 |
| Net profit / loss | 327.00 | 323.00 | 219.00 | 229.00 | 272.00 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 169.23 | 169.23 | 169.23 | 169.23 | 169.23 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 34.30 | 34.75 | 30.10 | 31.50 | 32.16 |
| GPM (%) | 31.19 | 30.86 | 26.21 | 27.19 | 29.35 |
| NPM (%) | 15.13 | 15.15 | 11.25 | 12.23 | 14.03 |
Mutual Fund Selector
Find the fund that is right for you
© 2023 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis